Address: Lomonosovsky Prospect 38, office 11, Moscow, 119330,Russia
Tel: +7 495 956-11-32
Web: http://www.novonordisk.ru/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 30,000 employees in 76 countries, and markets its products in 179 countries.
Novo Nordisk products have been well-known for the Russian patients for more than 60 years. The representative office of the company was opened in Moscow in 1991 and currently there are more than 200 employees working in Russia.
The principles of corporate social responsibility are an integral part of the company’s worldwide development strategy. Novo Nordisk seeks to contribute to the development of diabetes care and improvement in peoples’ health in every country in which it operates. Thus Novo Nordisk has launched many well-known large-scale initiatives in Russia. Mobile Diabetes Centre designed and developed jointly with the Health Ministry of Russia and Endocrinology Research Center is one of the projects. During 2002-2009 it carried out twenty-four scientific and practical expeditions to various parts of Russia, and more than 23 thousand people were examined.
Novo Nordisk also helps endocrinologists from Russia and CIS countries to improve their skills and update their knowledge on diabetes treatment. Every year more than 1,200 doctors are trained in the Novo Nordisk Medical Education and Information Center based in Moscow.
Novo Nordisk actively collaborates with diabetes associations in Russia and the CIS and the International Diabetes Federation (IDF), which has repeatedly awarded the company as the best corporate partner. In 2004, Novo Nordisk joined forces with Russian diabetes associations to hold Diabetes Days in the Interparliamentary Assembly of Member Nations of the CIS and, from 2005 to 2009, in the State Duma and Council of Federations of Russia.
Novo Nordisk continues to mount campaigns, drawing attention to the problems of diabetes. In 2006, Novo Nordisk supported the international campaign which helped drive the adoption of a UN Resolution on diabetes and continues to play an active role in the implementation of the aims and tasks of this campaign. In 2008-2009 Novo Nordisk acted as a general partner of the International Forum “Unite to Change Diabetes” in Moscow and St. Petersburg Forum “Diabetes. It’s Time to Act”.
In 2010, Novo Nordisk signed an agreement to set up a high technology and fully GMP compliant production of modern insulin products on the territory of Russia. By doing this the company demonstrates its willingness to create benefits for people with diabetes in Russia and also to contribute to the development of an innovation based pharmaceutical industry in Russia in line with the State Pharma 2020 Strategy.
Diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
